Bioventus Invests in CartiHeal Study

Bioventus invested US $2.5MM in the ongoing clinical study of CartiHeal's Agili-C™ implant for the treatment of joint surface lesions. The infusion adds to a previous raise of $18.3MM and brings CartiHeal's funding total to ~$21MM.

The Investigational Device Exemption trial kicked off in early 4Q17 with enrollment of 16 patients; since then,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us